Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS-866DM phase 3 clinical study: A double-blind controlled trial in patients with diabetic nephropathy and overt proteinuria secondary to type 2 diabetes mellitus.

Next Previous
Trial Profile

CS-866DM phase 3 clinical study: A double-blind controlled trial in patients with diabetic nephropathy and overt proteinuria secondary to type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ORIENT

    • Most Recent Events

    • 06 Dec 2011 Actual completion date changed to 01 Feb 2008 after recommendations from IDMC suggested primary endpoint was reached, according to report in Diabetologia.
    • 13 Oct 2011 Results published in the Diabetologia.
    • 01 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by clinicaltrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top